Answers are grounded in this paper and cite their sources.
The currently available photodynamic sensitizers usually lead to undesirable side effects, including dark toxicity from heavy-atom effect and nonspecific phototoxicity. To address these issues, we designed and prepared a smart photosensitizer from boron dipyrromethene (BODIPY), and the dark toxicity and phototoxicity were reduced via heavy-atom-free substitution and controllable photosensitization, respectively. Importantly, the photodynamic effect together with fluorescence imaging can be simultaneously switched on through the suppression of intramolecular charge transfer (ICT) and photoinduced electron-transfer (PeT) induced by cancer-related biothiol glutathione (GSH) in a buffer solution. Moreover, the sensitizer exhibits obvious fluorescence enhancement and selective phototoxicity towards cancer cells in a biological system upon irradiation. The present monochromatic photosensitizer, which combines fluorescence imaging and targeted PDT treatment within a single chromophore, possesses great potentials as a new activatable theranostic reagent in cancer therapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: